Athersys Inc., of Cleveland, said it entered an agreement with Healios KK, of Tokyo, to expand their collaboration into additional therapeutic areas. Under the terms, Healios obtained exclusive licenses for the development and commercialization in Japan of Multistem therapy for the treatment of acute respiratory distress syndrome (ARDS) and for Multistem cells used in combination with induced pluripotent stem cell (iPSC)-derived cells for the treatment of certain organs.